ong-Term Follow-up Protocol for Subjects Treated with JCAR015

Phase 1

• Conditions: B-cell Acute Lymphoblastic Leukemia (ALL); MedDRA version: 19.0Level: LLTClassification code 10000845Term: Acute lymphoblastic leukemiaSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Immune System Diseases [C20]

• Registration Number: EUCTR2016-003400-31-BE
• Lead Sponsor: Celgene Corporation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2016-11-17
• Last Update Posted: 28 August 2017

Recruitment & Eligibility

• Status: Authorised-recruitment may be ongoing or finished
• Sex: All
• Target Recruitment: 105

Inclusion Criteria

Subjects who received at least one dose of JCAR015 in a previous treatment protocol, and have discontinued, or completed the post-treatment follow-up period in a previous JCAR015 protocol, as applicable
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 105
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not Applicable.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified